Simponi

Simponi is indicated for the treatment of pediatric patients with ulcerative colitis (UC). In clinical trials, Simponi demonstrated a clinical response at Week 6 in 51% of patients, with a treatment difference of 21% compared to a comparator arm (30%). Clinical remission at Week 6 was observed in 18% of patients, showing an 11% treatment difference over a comparator arm (6%). Improvement of endoscopic appearance of the mucosa at Week 6 was achieved in 42% of patients, with a 14% treatment difference compared to a comparator arm (29%). For pediatric patients, clinical remission at Week 6 was 32%. Clinical response through Week 54 was 50%, with a treatment difference of 19% over a comparator arm (31%). Clinical remission at both Week 30 and Week 54 was 28%, with a 12% treatment difference over a comparator arm (16%).

Safety findings include an incidence of antibodies to golimumab of 21.7% in Study UCO3003, with 20% of those positive for antibodies having neutralizing antibodies. The overall incidence of anti-drug antibody (ADA) in adult studies was 21.3%. Injection-site reactions occurred in 3.6% of subjects negative for antibodies to golimumab and 15.4% in subjects positive for antibodies to golimumab. The background risk of major birth defects in the U.S. general population is 2-4%, and the background risk of miscarriage is 15-20%. Golimumab has a half-life of 2 weeks and a bioavailability of 53%. The Efficacy Supplement for this indication was submitted on December 12, 2024.